Kathy georgia retina download#

The approval of SYFOVRE is based on positive results from the Phase 3 OAKS and DERBY studies at 24 months across a broad and representative population of patients. Thank you to all who helped make this moment a reality.' 'GA is a complex disease that the field has spent decades trying to address, so we are humbled and proud to bring forward the first-ever treatment. With its increasing effects over time and flexible dosing, we believe that SYFOVRE will make a meaningful difference in the lives of people with GA,' said Cedric Francois, M.D., Ph.D., Co-founder and Chief Executive Officer, Apellis. 'Today marks an extraordinary milestone for patients, the retina community, and Apellis. On average, it takes only 2.5 years for GA lesions to start impacting the fovea, which is responsible for central vision (source 3). The vision loss caused by GA severely impairs independence and quality of life by making it difficult to participate in daily activities. It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision. GA is an advanced form of Age-Related Macular Degeneration (AMD). We are so thankful to the countless number of patients who participated in the clinical trials over the years to help bring this new treatment modality to fruition.' As with any new therapy that comes to market, patients with dry AMD will need to speak with their retina specialist to know if they are a candidate for this treatment. We are pleased that the results of the clinical trials demonstrated safety and effectiveness. 'It is very exciting to now have something to offer our dry AMD patients that has been scientifically and clinically proven to slow the progression of vision loss, and maintain their quality of life. Robert Stoltz, Director of Clinical Research Studies, Georgia Retina. However, those patients with dry AMD have not been so lucky. 'Over the last decade, we have seen many new therapies come to market for patients with wet AMD. We take special care to ensure that our study patients experience the best medical care possible. We partner with the National Eye Institute, some of the nation’s top pharmaceutical companies, and other clinical practices to explore the causes and cures for many retinal conditions. Georgia Retina has a long history of commitment to and participation in clinical trials to provide our patients access to new, state-of-the-art preventative, or therapeutic treatments. and five million people worldwide (source 1,2). GA is a leading cause of blindness that impacts more than one million people in the U.S.

Kathy georgia retina download#

Practice was amongst the first in the country to participate in the trialsĬlick here to download a photo of the SYFOVRE productįor further details about the SYFOVRE clinical study research, click here.ĪTLANTA, March 01, 2023-( BUSINESS WIRE)- Georgia Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy (GA).